التفاصيل البيبلوغرافية
| العنوان: |
Trends in Oral Anticoagulant Use and Individual Expenditures Across the United States from 2014 to 2020. |
| المؤلفون: |
Alkhezi, Omar S., Buckley, Leo F., Fanikos, John |
| المصدر: |
American Journal of Cardiovascular Drugs; May2024, Vol. 24 Issue 3, p433-444, 12p |
| مصطلحات موضوعية: |
WARFARIN, ANTICOAGULANTS, HEALTH status indicators, SOCIOECONOMIC factors, HEALTH insurance, INTERVIEWING, ORAL drug administration, ECONOMICS, PHARMACEUTICAL industry, SURVEYS, GENERIC drugs, DRUG utilization, TIME, MEDICAL care costs |
| مصطلحات جغرافية: |
UNITED States |
| مستخلص: |
Background: Landmark clinical trials have expended the indications for the direct oral anticoagulants (DOACs), but contemporary data on usage and expenditure patterns are lacking. Objective: This study aimed to assess annual trends in oral anticoagulant (OAC) utilization and expenditure across the United States (US) from 2014 to 2020. Methods: We utilized the Medical Expenditure Panel Survey (MEPS) to study the trends of use and expenditures of warfarin, dabigatran, rivaroxaban, apixaban, and edoxaban between 2014 and 2020 in the US. Survey respondents reported OAC use within the past year, which was verified against pharmacy records. Payment information was obtained from the respondent's pharmacy and was categorized as third-party or self/out-of-pocket. Potential indications and medical conditions of interest for OAC therapy were identified from respondent-reported medical conditions. We estimated the national number of OAC users and total expenditures across age, sex, race, ethnicity, insurance, and medical condition subgroups. Trends of OAC users' characteristics, expenditure, and number of prescriptions were evaluated using the Mann–Kendall test for trends. Results: Between 2014 and 2020, the number of warfarin users decreased from 3.8 million (70% of all OAC users) to 2.2 million (p = 0.007) [29% of all OAC users], while the number of DOAC users increased from 1.6 million (30% of all OAC users) to 5.4 million (p = 0.003) [70% of all OAC users]. The total expenditure of OACs in the US increased from $3.4 billion in 2014 to $17.8 billion in 2020 (p = 0.003), which was driven by the increase in DOAC expenditures (p = 0.003). Conclusions: DOACs have replaced warfarin as the preferred OAC in the US. The increased costs associated with DOAC use may decline when generic formulations are approved. [ABSTRACT FROM AUTHOR] |
|
Copyright of American Journal of Cardiovascular Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Find this article in full text from Springer Verlag. 
Full Text Finder